Company* (Symbol)

Product

Description

Indication

Status (Date)**

CANCER

AltaRex Corp. (Canada; TSE:AXO)

OvaRex MAb

Anti-idiotype induction therapy-based vaccine; consists of modified murine monoclonal antibody that binds to CA125 cancer antigen

Advanced-stage ovarian cancer

Presented retrospective data at the 31st Annual Meeting of the Society of Gynecologic Oncologists in San Diego (1/8)

OvaRex MAb

Anti-idiotype induction therapy-based vaccine; consists of modified murine monoclonal antibody that binds to CA125 cancer antigen

Advanced-stage ovarian cancer

Data Safety Monitoring Board recommended continuation of potentially pivotal trial (1/4)

Amgen Inc. (AMGN) and Praecis Pharmaceuticals Inc.*

Abarelix; synthetically modified peptide that acts as gonadotropin-releasing hormone antagonist

Prostate cancer

Completed two Phase III trials (1/25)

Atrix Laboratories Inc. (ATRX)

Atrigel formulation of leuprolide acetate; product is injected subcutaneously as a liquid, then solidifies and releases a predetermined dose of leuprolide continuously over a 30-day period as it is reabsorbed

Prostate cancer

In first 36 patients of ongoing Phase III trial, product reduced testosterone to levels known to inhibit tumor growth in prostate cancer (1/19)

Biomira Inc. (Canada; BIOM)

BLP 25 vaccine

Synthetic MUC-1 therapeutic vaccine; consists of 25-amino-acid sequence of the MUC-1 cancer mucin, encapsulated in liposomes; supresses tumor angiogenesis

Advanced non-small-cell lung cancer

Initiated second stage of Phase II trial program (1/25); presented Phase I and II data at a Keystone Symposium titled "Cellular Immunity and Immunotherapy of Cancer" in Santa Fe, N.M. (1/26)

British Biotech plc (UK; BBIOY)

Marimastat

Oral matrix metallo-proteinase inhibitor designed to inhibit blood flow to tumors

Advanced pancreatic cancer

Combination of marimastat and gemcitabine failed to show significant improvement in survival in multi-center pivotal Phase III trial; additional trials are slated to report in 2000 (1/25)

Cangene Corp. (Canada; TSE:CNJ)

Leucotropin

Granulocyte macrophage colony stimulating factor (GM-CSF)

Mobilization of peripheral blood stem cells in breast cancer patients

Cangene terminated U.S. Phase III trial early, citing slow recruitment and recent reports that high-dose chemotherapy and stem-cell transplantation may not be clinically superior to standard dose regimens in certain breast cancer patients (1/6)

Cephalon Inc. and TAP Holdings Inc. (partnership between Takeda Chemical Industries Ltd. [Japan] and Abbott Laboratories [NYSE:ABT])

CEP-701

Oral signal transduction modulator that inhibits certain growth factors by inhibiting the trk kinase

Prostate cancer

Initiated Phase II clinical program that includes a study in patients whose prostate is being surgically removed and a study in patients with hormone-resistant tumors (1/12)

Dendreon Corp.*

Therapeutic cancer vaccine that involves the isolation of a patient's dendritic cells and activation of these cells using a prostate tumor vaccine

Advanced prostate cancer

Initiated treatment in Phase III trial (1/26)

Genta Inc. (GNTA)

G3139

Antisense drug that targets mRNA produced by the bcl-2 gene, which is believed to be an apoptosis inhibitor

Relapsed small-cell lung cancer

National Cancer Institute initiated Phase I/II study of G3139 in combination with paclitaxel (1/5)

Human Genome Sciences Inc. (HGSI)

Repifermin

Keratinocyte growth factor-2 therapeutic protein (genomics derived); KGF-2 is activated when there is an epithelial tissue wound

Mucositis associated with bone marrow transplantation for treatment of cancer

Initiated dosing in Phase II trial (1/19)

Immunomedics Inc. (IMMU)

CEA-Cide

Humanized antibody against carcinoembryonic antigen; radiolabeled with yttrium-90

Advanced, metastatic medullary thyroid cancer

Data from 12-patient proof-of-principle trial published in 1/00 issue of The Journal of Nuclear Medicine (1/26)

Isis Pharmaceuticals Inc. (ISIP)

ISIS 5132

Antisense oligonucleotide that targets c-raf-1 mRNA expression

Advanced-stage cancer

Mechanism of action trial data published in 12/99 issue of Clinical Cancer Research (1/12)

Matrix Pharmaceutical Inc. (MATX)

Intradose injectable gel

Biodegradable gel containing cisplatin and epinephrine (intra-tumoral injection)

Recurrent or refractory head and neck cancer

Completed enrollment in two Phase III registration-directed trials (1/13)

NeoRx Corp. (NERX)

Skeletal Targeted Radiotherapy

Product delivers holmium-166 radionuclide to bone and adjacent bone marrow

Multiple myeloma

Reported Phase I trial results and that Phase II enrollment is close to completion (1/13)

Neurocrine Biosciences Inc. (NBIX)

NBI-3001

Blood cell-derived growth factor (IL-4, which binds to IL-4 receptors on malignant brain tumors) combined with Pseudomonas exotoxin (an anticancer toxin); product is administered via a special catheter that permits delivery directly into brain tumor

Glioblastoma multiforme malignant brain tumors

Neurocrine presented a review of data from an ongoing Phase I/II trial at the First Union Securities Brain and Spine Symposium conference (1/19)

CARDIOVASCULAR

3-Dimensional Pharmaceuticals*

3DP 4815

Oral anticoagulant thrombin inhibitor

Arterial and venous thrombosis

Initiated Phase I trial (1/20)

AVANT Immunotherapeutics (AVAN)

TP10

Soluble form of complement receptor 1 (CR1), designed to inhibit complement proteins

Reduction of consequences of reperfusion injury in infants undergoing cardiopulmonary bypass

Completed enrollment in open label Phase II trial (1/13)

BioPure Corp. (BPUR)

Hemopure

Hemoglobin glutamer-250 (bovine); each unit of product contains approximately 30 grams of purified, chemically cross-linked hemoglobin in 250 ml of a balanced salt solution

Alternative to red blood cell transfusion in orthopedic surgery

Continued to enroll patients in pivotal Phase III trial following independent panel's review of safety data at the halfway point of the trial (1/12)

Genzyme Transgenics Corp. (GZTC) and Genzyme General (GENZ)

Recombinant human antithrombin III (rhATIII) produced in transgenic mammals

Restoration of heparin sensitivity in heparin-resistant patients

Reported results of Phase III trial that met primary endpoint of reduction in the use of fresh frozen plasma (1/10)

Hemosol Inc. (Canada; TSE: HML)

Hemolink

Hemoglobin replacement product derived from red blood cells

Coronary artery bypass grafting surgery

Completed Phase II trial (1/10)

Transkaryotic Therapies Inc. (TKTX) and Aventis SA (NYSE:AVE)

GA-EPO

Gene-activated erythropoietin; gene in human cells is activated in situ to produce EPO

Anemia of renal failure in dialysis and pre-dialysis patients

Completed dosing in pivotal Phase III trials (1/11)

CENTRAL NERVOUS SYSTEM

Cellegy Pharmaceuticals Inc. (CLGY)

Anogesic in a proprietary formulation

Nitroglycerin ointment

Reduction of pain associated with hemorrhoid surgery

Expanded and accelerated Phase II trial following findings from Phase III study in pain reduction of anal fissures (1/20)

Cephalon Inc. (CEPH)

Provigil tablets (FDA-approved)

Modafinil; oral formulation of synthetic compound that is thought to affect alpha-adrenergic receptors in the brain

Multiple sclerosis fatigue

Reported data from placebo-controlled study (1/13)

Provigil tablets (FDA-approved)

Modafinil; oral formulation of synthetic compound that is thought to affect alpha-adrenergic receptors in the brain

Improvement of performance and alertness during shift work

Reported data from placebo-controlled study (1/13)

Interneuron Pharmaceuticals Inc. (IPIC) and Takeda Chemical Industries Ltd. (Japan)

CerAxon

Citicholine sodium; organic molecule that consists of cytidine and choline (components of brain cell membranes)

Moderate to severe ischemic stroke

Failed to meet primary endpoint improvement in neurological function in Phase III trial (1/10)

Orphan Medical Inc. (ORPH)

Xyrem

Sodium oxybate oral solution

Narcolepsy symptoms of cataplexy and excessive daytime sleepiness

Results of two pivotal Phase II clinical trials were presented at the First Union Securities Brain and Spine Conference in New York (1/19)

Neurobiological Technologies Inc. (OTC BB:NTII) and Merz + Co. GmbH & Co. (Germany)

Memantine

Orally available neuro-protective agent that appears to restore damaged nerve cells and block excitatory signals by modulating the N-methyl-D-aspartate (NMDA) receptor on cell membranes

AIDS-related dementia

Completed enrollment in Phase II trial (1/31)

Sepracor Inc. (SEPR)

Single-isomer form of desmethylsibutramine, a serotonin, norepin-ephrine and dopamaine re-uptake inhibitor (single-isomer form of Meridia, marketed by Knoll Pharmaceutical Co. [unit of BASF AG; Germay])

Multiple CNS indications including depression and attention deficit hyperactivity disorder

Initiated Phase I trial (1/31)

Single-isomer form of zopiclone, a non-benzodiazepine rapid-acting hypnotic (single-isomer form of Imovane, marketed by Rhone-Poulenc Rorer Inc. [NYSE:RPR])

Insomnia

Initiated efficacy trial (1/18)

DIABETES

Amylin Pharmaceuticals Inc. (AMLN)

AC2993

Synthetic exendin-4

Type II diabetes

Reported preliminary results of dose-finding Phase II study (1/7); reported additional analyses from Phase II trial first reported 10/99 (1/10)

Diamyd Medical AB (Sweden; SBI: DIAMb)

Diamyd

Type I diabetes vaccine; recombinant human GAD65 (glutamic acid decarboxylase)

Treatment and/or prevention of Type I diabetes

Completed Phase I trial; data reported at Miami meeting of the National Institute of Diabetes and Digestive and Kidney Diseases (1/31)

Generex Biotechnology Corp. (Canada; OTC BB:GNBT)

Oralin/Oralgen

Oral form of insulin

Type I diabetics and healthy volunteers

Completed short-term trials (1/12)

Neurobiological Technologies Inc. (OTC BB:NTII) and Merz + Co. GmbH & Co. (Germany)

Memantine

Orally available neuro-protective agent that appears to restore damaged nerve cells and block excitatory signals by modulating the N-methyl-D-aspartate (NMDA) receptor on cell membranes

Painful diabetic neuropathy

Reported preliminary results of Phase IIb dose-ranging trial (1/19)

INFECTION

Agouron Pharmaceuticals Inc. (subsidiary of Warner-Lambert Co.; NYSE: WLA)

Capravirine; non-nucleoside reverse transcriptase inhibitor

HIV infection

Reported data from second pharmacokinetic trial; data from both trials presented at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco (1/30)

Viracept (FDA- approved)

Nelfinavir mesylate; HIV protease inhibitor

HIV infection

Presented data from three trials at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco (1/30)

AVANT Immunotherapeutics Inc. (AVAN)

Peru-15

Cholera vaccine

Prevention of cholera infection

AVANT will collaborate with the Walter Reed Army Institute of Research and the National Institutes of Health on a Phase IIb scheduled to begin this year (1/18)

The Immune Response Corp. (IMNR) and Agouron Pharmaceuticals Inc. (subsidiary of Warner-Lambert Co.; NYSE:WLA)

Remune

Envelope-depleted, inactivated HIV (emulsified with adjuvant)

HIV infection

Facility-sponsored trial at Cedars-Sinai Medical Center in Los Angeles will test Remune in combination with highly active antiretroviral therapy in early-stage HIV infection (1/25)

Micrologix Biotech Inc. (Canada; TSE: MBI)

MBI 226

Peptide antibiotic

Prevention of central venous catheter-related bloodstream infection

Completed Phase II trial and reported results (1/12)

Peptide Therapeutics Group (LSE:PTE)

Vaccine against Clostridium difficile-associated diarrhea and colitis

Clostridium difficile-associated diarrhea and colitis

Reported results of Phase I/II trial funded by the National Institute of Allergy and Infectious Diseases and conducted by Peptide Therapeutics' U.S. subsidiary, OraVax Inc. (1/20)

SciClone Pharmaceuticals (SCLN)

Zadaxin

Thymosin alpha 1; synthetic version of naturally occuring peptide hormone thymosin (immunomodulator)

Hepatitis B virus infection

Initiated Phase II trial of Zadaxin in combination with lamivudine, an FDA-approved nucleoside analogue marketed by BioChem Pharma Inc. (Canada; BCHE) (1/27)

Trimeris Inc. (TRMS) and Hoffmann-La Roche Inc. (Switzerland)

T-20

Antiviral fusion-inhibiting compound (twice-daily subcutaneous injection)

HIV infection

Reported 32-week results from ongoing open-label Phase II trial of T-20 in combination regimen (1/28)

Vical Inc. (VICL) and Merck & Co. Inc. (NYSE: MRK)

Naked DNA vaccine; intramuscular injection

Prevention of HIV infection

Initiated Phase I trial (1/7)

MISCELLANEOUS

Aradigm Corp. (ARDM) and Genentech Inc. (NYSE:DNA)

Inhalation solution of recombinant human dornase alfa (active ingredient of Genentech's Pulmozyme)

Cystic fibrosis

Initiated Phase IIa trial (1/24)

Carrington Laboratories Inc. (CARN)

Aliminase (formerly CARN 1000)

Oral anti-inflammatory complex carbohydrate

Ulcerative colitis

Completed patient enrollment in Phase III trial (1/12)

Discovery Laboratories Inc. (DSCO)

Surfaxin

Lucinactant (sinapultide); lung surfactant containing the peptide KL4, a 21-amino-acid peptide modeled after the SP-B protein in the human surfactant system

Full-term infants with meconium aspiration syndrome

Initiated pivotal Phase III trial (1/27)

Surfaxin

Lucinactant (sinapultide); lung surfactant

Acute respiratory distress syndrome containing the peptide KL4, a 21-amino-acid peptide modeled after the SP-B protein in the human surfactant system

Halted Phase II/III trial due to improved manufacturing process allowing for less viscous formulation; company plans to initiate new trial in the indication with new formulation (1/27)

Emisphere Technologies Inc. (EMIS) and Novartis Pharma (Switzerland)

Solid oral dosage form of calcitonin

Osteoporosis

Reported results of Phase I trial (1/11)

ICOS Corp. (ICOS)

IC351

Inhibits cGMP-destroying enzyme PDE5, thus allowing cGMP to accumulate and reinforce signal to increase blood flow

Erectile dysfunction and female sexual dysfunction

Began enrollment of healthy female volunteers for pharmacokinetic studies (1/12)

Pafase (formerly rhPAF-AH)

Recombinant platelet activating factor acetylhydrolase; degrades PAF and thereby lessens inflammatory response

Prevention of acute respiratory distress syndrome in at-risk patients

Completed enrollment in Phase II trial (1/12)

Inspire Pharmaceuticals Inc.*

INS365 Ophthalmic Solution

Small molecule that stimulates the P2Y2 receptor, a key mediator of mucosal hydration and mucociliary clearance

Dry-eye disease

Initiated Phase II trial (1/5)

OrthoLogic Corp. (OLGC)

Chrysalin

Synthetic peptide that represents a portion of the receptor binding domain of the human thrombin molecule; by mimicking specific attributes of thrombin, product stimulates healing processes

Fractures

Initiated enrollment in Phase I/II trial (1/12)

Notes:

* Indicates a privately held company

** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SBI=Stockholm Borsinformation; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange

ND = Not disclosed

No Comments